JPMorgan analyst Rachel Vatnsdal raised the firm’s price target on Natera (NTRA) to $200 from $160 and keeps an Overweight rating on the shares. The firm updated the company’s model to reflect information from the latest quarterly filing as well as adjustments to 2025 estimates, profitability estimates.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Natera enrolls 1st patients in SAGITTARIUS clinical trial in colon cancer
- Natera Aligns Executive Chairman’s Pay with Performance
- Natera publishes cfDNA data in Obstetrics & Gynecology
- Guardant says jury unanimously found in favor of company in Natera suit
- Natera ‘disagrees’ with jury’s decision in Guardant Health litigation